AbbVie: Ulcer trials

The registry lists 28 Ulcer studies with AbbVie as lead sponsor. 0 are open to participants now and 19 have results posted.

Phase 1 3Phase 2 3Phase 3 15No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior TherapyCompletedNCT03695185Phase 2Results posted
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT03653026Phase 3Results posted
• A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT03398148Phase 2/3Results posted
• A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)CompletedNCT02819635Phase 2/3Results posted
• A Prospective Non-interventional Multicenter Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical PracticeCompletedNCT02499263Results posted
• Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuoTerminatedNCT02092389Results posted
• Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative ColitisCompletedNCT02065622Phase 3Results posted
• Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative ColitisCompletedNCT02065557Phase 3Results posted
• Special Investigation in Patients With Ulcerative ColitisCompletedNCT01947816Results posted
• Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical PracticeCompletedNCT01768858Results posted
• A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice SettingCompletedNCT01550965Phase 3Results posted
• Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative ProctitisTerminatedNCT01016262Phase 3Results posted
• Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative ColitisTerminatedNCT01004185Phase 3Results posted
• A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative ColitisCompletedNCT00853099Phase 3Results posted
• Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative ColitisCompletedNCT00713310Phase 3Results posted
• Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)CompletedNCT00577473Phase 3Results posted
• Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative ColitisCompletedNCT00573794Phase 3Results posted
• A Comparison of Once a Day Dose Compared to 2 Doses/DayCompletedNCT00505778Phase 3Results posted
• Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative ColitisCompletedNCT00073021Phase 3Results posted
• Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative ColitisCompletedNCT04862741Phase 1
• A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's DiseaseCompletedNCT04254783Phase 1
• Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health ServiceCompletedNCT03223012
• Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life ConditionsCompletedNCT02738125
• Impact of Adalimumab on Patient-reported Outcomes in Ulcerative ColitisCompletedNCT02506179
• A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell LymphomaWithdrawnNCT02087878
• Fecal Biomarker Study for Patients With Ulcerative ColitisCompletedNCT00780507
• A Double Blind Study for the Treatment of Acute Ulcerative ColitisCompletedNCT00350415Phase 3
• A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis.TerminatedNCT00254618Phase 1